Open AccessEffectiveness of omalizumab in patients with chronic spontaneous and inducible urticaria
Author(s) -
Д. М. Скандер,
Anastasiia Allenova,
М. Л. Самсонян,
Pavel Kolkhir
Publication year - 2019
Publication title -
medicinskij alfavit
Language(s) - English
Resource type - Journals
eISSN - 2949-2807
pISSN - 2078-5631
DOI - 10.33667/2078-5631-2019-2-21(396)-5-8
Subject(s) - omalizumab , medicine , concomitant , antihistamine , provocation test , chronic urticaria , guideline , adverse effect , dermatology , immunoglobulin e , antibody , anesthesia , immunology , pathology , alternative medicine
Background. Omalizumab, a recombinant humanized anti-IgE antibody, is an effective treatment option for patients with antihistamine-resistant chronic spontaneous urticaria (CSU). 14–36 % of CSU patients have concomitant chronic inducible urticaria (CIndU). However, it is unclear whether CSU patients with comorbid CIndU can benefit from this treatment. Aim of the study. To assess the efficacy and safety of omalizumab in two patients with CSU and several of types of concomitant CIndU. Materials and methods. CSU and CIndU were diagnosed as recommended by the international urticaria guideline. Both female patients were treated with omalizumab 300 mg by subcutaneous injection every 4 weeks. Response to treatment was assessed by a carefully determined history, the urticaria activity score, urticaria control test, and results of provocation testing. Results. Symptoms of both CSU and CIndU decreased dramatically during the first week of treatment. No adverse events were documented. Conclusions. Omalizumab may be an effective treatment option for patients with combination of antihistamine-resistant CSU and concomitant CIndU. Our findings should be confirmed in larger prospective studies.